googlea5e4f24c126ec886.html
top of page
Alcresta_Therapeutics_Logo.jpg

Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital. Our RELiZORB® cartridge contains iLipase®, a patented microbead/enzyme technology that breaks down fat for easy ingestion and optimal absorption.

Contact us

Amy Whited

 Account Manager

 awhited@alcresta.com

(860) 305-6570

Website: Alcresta.com

General email: Info@alcresta.com

ABOUT US

The Collaborative Alliance for Pancreatic Education and Research’s (CAPER) mission is: (a) to facilitate the collaboration of researchers of pancreatic diseases and to support scientifically rigorous multi-center studies in pancreatic diseases; (b) to educate and train healthcare providers in pancreatic diseases; (c) and to increase public health awareness regarding pancreatic diseases.

  • Facebook
  • Twitter
  • YouTube
  • Instagram

© 2024 Collaborative Alliance for Pancreatic Education and Research

When you visit this website, CAPER and its affiliates process personal data about you. 

For more information regarding this process, please consult our CAPER Privacy Policy.

bottom of page